Profile data is unavailable for this security.
About the company
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. It is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The Company's ongoing programs include SLS-004, SLS-006, SLS-007 and SLS-008.
- Revenue in USD (TTM)0.00
- Net income in USD-82.14m
- Incorporated1987
- Employees16.00
- LocationSeelos Therapeutics Inc300 PARK AVENUE, 2ND FLOORNEW YORK 10022United StatesUSA
- Phone+1 (646) 293-2100
- Fax+1 (858) 436-8155
- Websitehttps://seelostherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NuCana PLC (ADR) | 0.00 | -36.72m | 83.51m | 31.00 | -- | 1.32 | -- | -- | -0.7075 | -0.7075 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -38.46 | -31.30 | -46.56 | -33.71 | -- | -- | -- | -- | -- | -- | 0.0128 | -- | -- | -- | -32.11 | -- | 13.96 | -- |
| Passage Bio Inc | 0.00 | -160.21m | 84.56m | 133.00 | -- | 0.3768 | -- | -- | -2.95 | -2.95 | 0.00 | 4.11 | 0.00 | -- | -- | 0.00 | -48.47 | -- | -51.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -65.18 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 0.00 | -60.31m | 84.61m | 2.00 | -- | 5.04 | -- | -- | -0.9869 | -0.9869 | 0.00 | 0.2481 | 0.00 | -- | -- | -- | -172.12 | -- | -477.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -31,922.19 | -- | -- | -- |
| Longeveron Inc | 1.31m | -18.45m | 84.91m | 18.00 | -- | 3.45 | -- | 64.82 | -0.8892 | -0.8892 | 0.0632 | 1.17 | 0.0454 | -- | 7.53 | 72,777.78 | -63.98 | -- | -70.93 | -- | 47.40 | -- | -1,408.17 | -- | -- | -55.93 | 0.00 | -- | -76.80 | -- | -358.10 | -- | -- | -- |
| Cardiff Oncology Inc | 391.00k | -39.47m | 86.23m | 22.00 | -- | 0.7388 | -- | 220.53 | -0.9262 | -0.9262 | 0.0092 | 2.61 | 0.003 | -- | 0.7483 | 17,772.73 | -29.78 | -38.88 | -31.35 | -42.83 | -- | -- | -10,089.26 | -5,685.91 | -- | -- | 0.00 | -- | -1.91 | -1.19 | -25.30 | -- | -24.28 | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -41.37m | 86.42m | 21.00 | -- | 1.20 | -- | -- | -2.42 | -2.42 | 0.00 | 4.19 | 0.00 | -- | -- | 0.00 | -42.09 | -- | -44.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.03 | -- | -- | -- |
| Lyra Therapeutics Inc | 1.62m | -54.66m | 87.52m | 53.00 | -- | 0.9389 | -- | 53.93 | -2.26 | -2.26 | 0.0682 | 2.93 | 0.0173 | -- | -- | 30,622.64 | -58.39 | -- | -70.15 | -- | -- | -- | -3,367.84 | -- | -- | -- | 0.00 | -- | -- | -- | -95.63 | -- | -- | -- |
| Eton Pharmaceuticals Inc | 18.85m | -8.89m | 88.29m | 17.00 | -- | 7.90 | -- | 4.68 | -0.3516 | -0.3516 | 0.7458 | 0.442 | 0.7832 | 12.13 | 20.02 | 1,108,588.00 | -36.96 | -- | -46.68 | -- | 73.77 | -- | -47.19 | -- | 3.42 | -9.40 | 0.3635 | -- | 55,879.49 | -- | 93.01 | -- | -- | -- |
| Eliem Therapeutics Inc | 0.00 | -48.03m | 89.53m | 43.00 | -- | 0.6664 | -- | -- | -1.83 | -1.83 | 0.00 | 5.06 | 0.00 | -- | -- | 0.00 | -29.73 | -- | -30.86 | -- | -- | -- | -- | -- | -- | -19.14 | 0.00 | -- | -- | -- | -126.67 | -- | -- | -- |
| Seelos Therapeutics Inc | 0.00 | -82.14m | 90.25m | 16.00 | -- | 11.45 | -- | -- | -0.7795 | -0.7795 | 0.00 | 0.0735 | 0.00 | -- | -- | 0.00 | -135.25 | -190.52 | -179.47 | -336.13 | -- | -- | -- | -40,434.13 | -- | -284.81 | 0.7309 | -- | -- | -- | -245.78 | -- | -- | -- |
| Clearside Biomedical Inc | 26.68m | -4.58m | 90.89m | 34.00 | -- | 4.90 | -- | 3.41 | -0.1009 | -0.1009 | 0.4343 | 0.3081 | 0.6425 | -- | -- | 784,823.50 | -11.02 | -97.86 | -13.32 | -131.58 | -- | -- | -17.15 | -475.79 | -- | -- | 0.00 | -- | 274.65 | 124.38 | 102.06 | -- | -- | -- |
| Fortress Biotech Inc | 77.62m | -91.19m | 91.81m | 173.00 | -- | 1.48 | -- | 1.18 | -1.05 | -1.05 | 0.892 | 0.5697 | 0.2122 | 2.43 | 2.58 | 448,641.60 | -61.52 | -48.58 | -124.16 | -96.80 | 58.02 | 65.67 | -289.86 | -306.33 | 2.28 | -14.81 | 0.5008 | -- | 50.86 | 33.08 | -39.07 | -- | -5.87 | -- |
| Eiger Biopharmaceuticals Inc | 14.15m | -93.41m | 92.56m | 54.00 | -- | 1.18 | -- | 6.54 | -2.41 | -2.41 | 0.362 | 1.78 | 0.0996 | 0.587 | 5.42 | 524,000.00 | -65.77 | -54.15 | -79.19 | -63.00 | 88.72 | -- | -660.21 | -2,174.76 | 5.34 | -28.22 | 0.3343 | -- | -- | -- | 47.86 | -- | 31.14 | -- |
| Achieve Life Sciences Inc | 0.00 | -38.27m | 93.06m | 16.00 | -- | 48.37 | -- | -- | -3.99 | -3.99 | 0.00 | 0.1075 | 0.00 | -- | -- | 0.00 | -124.41 | -68.48 | -148.53 | -79.40 | -- | -- | -- | -- | -- | -32.00 | 0.9379 | -- | -- | -- | -125.06 | -- | -- | -- |
| Eyenovia Inc | 10.00m | -18.90m | 97.17m | 43.00 | -- | 4.70 | -- | 9.72 | -0.5642 | -0.5642 | 0.3168 | 0.5722 | 0.3546 | -- | 7.44 | 232,558.10 | -67.04 | -82.88 | -153.31 | -124.23 | 100.00 | -- | -189.04 | -475.55 | -- | -29.23 | 0.2623 | -- | 600.00 | -- | 35.36 | -- | 95.35 | -- |
Data as of Feb 03 2023. Currency figures normalised to Seelos Therapeutics Inc's reporting currency: US Dollar USD
20.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2022 | 4.98m | 4.65% |
| Tontine Associates LLCas of 30 Sep 2022 | 4.91m | 4.58% |
| Uniplan Investment Counsel, Inc.as of 30 Sep 2022 | 2.49m | 2.32% |
| Group One Trading LPas of 30 Sep 2022 | 2.16m | 2.02% |
| BlackRock Fund Advisorsas of 30 Sep 2022 | 1.78m | 1.66% |
| Horizons ETFs Management (Canada), Inc.as of 30 Sep 2022 | 1.76m | 1.64% |
| MAI Capital Management LLCas of 30 Sep 2022 | 1.23m | 1.15% |
| Geode Capital Management LLCas of 30 Sep 2022 | 1.11m | 1.03% |
| Millennium Management LLCas of 30 Sep 2022 | 919.07k | 0.86% |
| Oasis Management (Hong Kong) LLCas of 30 Sep 2022 | 850.00k | 0.79% |
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
